An observational study in Intracardiac Thrombus, Intracardiac Mass and Intravascular Thrombosis, sponsored by Charite University, Berlin, Germany. Not yet recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Charite University, Berlin, Germany · Observational
As a structured, multinational retrospective registry the AVATAR Registry addresses the following scientific aspects through systematic data collection, centralized quality control, and robust statistical analysis in patients that were treated with the AngioVac Aspiration System:
Generate Publishable Cohorts: Sufficient statistical power (approx. 1000 patients across 8 indication cohorts) for:
The AngioVac Aspiration System is a percutaneous device that enables removal of intravascular and intracardiac thrombotic or infectious material using a venovenous extracorporeal circuit with blood filtration and reinfusion. The system combines:
The AngioVac applications include the following clinical situations:
Despite increasing clinical adoption, the evidence base remains limited:
22 studies on the registry are indexed under Endocarditis, Bacterial; 9 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 588 across 10 observational studies indexed under Endocarditis, Bacterial.
Browse Endocarditis, Bacterial studies →Charite University, Berlin, Germany is the lead sponsor of 857 studies on the registry; 129 are open to participants now.
Compared within Endocarditis, Bacterial, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Endocarditis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
All patients who underwent an AngioVac procedure during the specified and mentioned time period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants are not assigned an intervention as part of the study
Safety and technical effectiveness of AngioVac
Evaluation of in-hospital safety and procedural effectiveness of AngioVac in real-world practice across indications.
Time frame: From intervention to the end of 12month
Various secondary endpoints
Indication-stratified outcomes, predictors of technical success and adverse events, procedural resource use, device-related complications, and 30-day / 12-month follow-up where available.
Time frame: From intervention to the end of 12month
Plan to share: Yes — Data from the study can be made available upon request from the study lead in a de-identified form. A data use agreement must be signed before access to data. Access is only granted to academic staff.
Supporting information: Study protocol
Time frame: see above
Access criteria: see above
Start is estimated for Oct 2026; primary completion for Dec 2027, 14 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Charite University, Berlin, Germany →